At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 129 enrolled
Drug / intervention
Detrusitol 4mg QD and Oxybutynin ER 5mg QD +1 moredrug
Likely dose
Detrusitol 4mg QD and Oxybutynin ER 5mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy
In Brief
A Phase 4 clinical trial evaluating Detrusitol 4mg QD and Oxybutynin ER 5mg QD and Detrusitol 4mg QD for Overactive Bladder. Completed, enrolled 129 participants across 1 site.
Detailed Summary
To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedApr 2013
Primary CompletionFeb 2017
TodayJul 2026
First PostedApr 4, 2013
Enrollment StartMar 1, 2013
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 13.2 years ago
Interventions
Detrusitol 4mg QD and Oxybutynin ER 5mg QDdrug
Study group
Detrusitol 4mg QDdrug
Control group